20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
At the present time, there are no technological gaps to fill, although we expect the R&D activity to produce continuous improvements in the technology performance in the future. BIOSCIENCE GENOMICS’s main goals will be to simplify the process, improve its accuracy, and reduce its costs. Moreover, we aim at integrating the IMMUNEBALANCE results with anamnestic data and results from the other tests through our AI. Consequently, we will need validation of the AI’s ability to integrate the information from IMMUNEBALANCE, with the anamnesis, and with the other HELIXAFE tests, to outline the individual based on the colorectal cancer risks they present. We also aim at combining IMMUNEBALANCE with the analysis of other cancer drivers (mitochondrial dysfunction), to further increase the immune imbalance analysis’ predictive value.
